Valeo Financial Advisors LLC Decreases Stock Position in The Cigna Group (NYSE:CI)

Valeo Financial Advisors LLC trimmed its holdings in shares of The Cigna Group (NYSE:CI) by 1.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,023 shares of the health services provider’s stock after selling 57 shares during the quarter. Valeo Financial Advisors LLC’s holdings in The Cigna Group were worth $1,111,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Collier Financial purchased a new stake in shares of The Cigna Group during the 4th quarter valued at about $32,000. ORG Wealth Partners LLC purchased a new stake in shares of The Cigna Group during the 4th quarter valued at about $34,000. Prospera Private Wealth LLC purchased a new stake in The Cigna Group in the 3rd quarter worth about $37,000. Compagnie Lombard Odier SCmA purchased a new stake in The Cigna Group in the 4th quarter worth about $37,000. Finally, Harbor Capital Advisors Inc. purchased a new stake in The Cigna Group in the 3rd quarter worth about $45,000. 86.99% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on CI. Cantor Fitzgerald reduced their price objective on shares of The Cigna Group from $400.00 to $350.00 and set an “overweight” rating on the stock in a research report on Friday, January 31st. Oppenheimer reduced their price objective on shares of The Cigna Group from $400.00 to $375.00 and set an “outperform” rating on the stock in a research report on Friday, January 31st. Morgan Stanley reduced their price objective on shares of The Cigna Group from $403.00 to $379.00 and set an “overweight” rating on the stock in a research report on Friday, January 31st. UBS Group reduced their price objective on shares of The Cigna Group from $410.00 to $390.00 and set a “buy” rating on the stock in a research report on Monday, February 3rd. Finally, Truist Financial dropped their target price on shares of The Cigna Group from $390.00 to $375.00 and set a “buy” rating on the stock in a research note on Tuesday, February 4th. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $373.69.

The Cigna Group Price Performance

NYSE CI opened at $292.12 on Monday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.72 and a current ratio of 0.66. The firm’s 50 day moving average price is $286.46 and its 200-day moving average price is $320.86. The Cigna Group has a 52-week low of $262.03 and a 52-week high of $370.83. The company has a market cap of $81.25 billion, a PE ratio of 23.87, a P/E/G ratio of 0.94 and a beta of 0.54.

The Cigna Group (NYSE:CI) last announced its earnings results on Thursday, January 30th. The health services provider reported $6.64 earnings per share for the quarter, missing the consensus estimate of $7.84 by ($1.20). The Cigna Group had a net margin of 1.39% and a return on equity of 18.61%. During the same quarter last year, the company earned $6.79 earnings per share. Sell-side analysts forecast that The Cigna Group will post 29.8 EPS for the current fiscal year.

The Cigna Group Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Wednesday, March 5th will be paid a $1.51 dividend. This represents a $6.04 annualized dividend and a yield of 2.07%. This is an increase from The Cigna Group’s previous quarterly dividend of $1.40. The ex-dividend date of this dividend is Wednesday, March 5th. The Cigna Group’s dividend payout ratio (DPR) is 45.75%.

The Cigna Group Company Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.